Taken together, increased levels of CAR and DSG2 could help target oncolytic adenovirus vectors for use as a therapeutic tool in lung cancer [5,21]; however, they also appear to indicate inferior survival outcomes in NSCLC [6,7,9,12,18,25,26,35]. The gene discussed is DSG2; the disease is non-small cell lung carcinoma.